FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE ATTORNEY DOCKET NO. PATENT AND TRADEMARK OFFICE (REV 5-93) P564-9010 TRANSMITTAL LETTER TO THE UNITED STATES **DATE: August 12, 1999** DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** U.S. APPLN. NO. (IF KNOWN, SEE 37 CFR 1.5) 09/297,092 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP97/06463 19 November 1997 19 November 1996

TITLE OF INVENTION: COMPOUNDS WITH IMPROVED CARTILAGE-INDUCING AND/OR BONE-INDUCING ACTIVITY

APPLICANT(S) FOR DO/EO/US: Michael PAULISTA, Jens POHL, Joachim PABST, Helmut HEIDE

- This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)
- 2. XX This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
- 3. _ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).
- 4. _ A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- 5. _ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. _ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. _ has been transmitted by the International Bureau.
 - c. _ is not required, as the application was filed in the United States Receiving Office (RO/US)
- 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- 7. _ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. _ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. _ have been transmitted by the International Bureau.
 - c. _ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. _ have not been made and will not be made.
- 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- 10. XX A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

- 11. _ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 12. Two assignment documents for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. _ A FIRST preliminary amendment.
 - _ A SECOND or SUBSEQUENT preliminary amendment.
- 14. _ A substitute specification.
- 15. _ A change of power of attorney and/or address letter.
- 16. _ Other items or information: CHECK NO.

99 AUG 16 AM T:

U.S. APPLN. NO. (IF KNO	OWN, SEE 37	INTERNATIONAL APPLICATION NO. PCT/EP97/06463		ATTORNEY DOCKET NO. P564-9010 DATE: August 12, 1999	
C.F.R. 1.50) 09/297,092					
17. XX The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO				CALCULATIONS	PTO USE ONLY
claims satisfied provisions of PCT Article 33(2)-(4)\$ 96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				\$00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	13 - 20 =	00	X \$ 18.00	\$00	
Independent Claims	01 - 3 =	00	X \$ 78.00	\$00	
Multiple dependent claim(s) (if applicable)		+ \$260.00	\$00	
	TOTAL OF ABOVE (CALCULATIONS =		\$00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$00	
SUBTOTAL =				\$00	
Processing fee of \$130.00 months from the earliest cla	for furnishing the Engaimed priority date (3	glish translation later 7 CFR 1.492(f)).	the _ 20 _ 30 +	\$00	
TOTAL NATIONAL FEE =				\$00	
Fee for recording the enclo be accompanied by an app property	sed assignment (37 ropriate cover sheet	CFR 1.21(h)). The a (37 CFR 3.28, 3.31)	ssignment must . \$40.00 per +	\$00	
		TOTAL FEES E	NCLOSED =	\$00	
				Amount to be refunded	\$
		· ·		Charged	\$

b. _ Please charge my Deposit Account No. <u>14-1060</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

NIKAIDO, MARMELSTEIN, MURRAY AND ORAM LLP Metropolitan Square 655 15th Street, N.W. Suite 330 - G Street Lobby Washington, D.C. 20005-5701 Telephone No. (202) 638-5000

Robert B. Murfay

Reg. No. 22,980

c. XX The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1060.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF TRANSMITTAL OF COPIES OF TRANSLATION OF THE INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

(PCT Rule 72.2)

From the INTERNATIONAL BUREAU CKMANN

To:

2 5. JUNI 1999

WEICKMANN, H. Kopernikusstrasse 9 D-81679 München **ALLEMAGNE**

Date of mailing (day/month/year) 09 June 1999 (09.06.99)

Applicant's or agent's file reference 15409P WO

International application No.

PCT/EP97/06463

IMPORTANT NOTIFICATION

International filing date (day/month/year) 19 November 1997 (19.11.97)

Applicant

BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBH et al

1. Transmittal of the translation to the applicant.

The International Bureau transmits herewith a copy of the English translation made by the International Bureau of the international preliminary examination report established by the International Preliminary Examining Authority.

2. Transmittal of the copy of the translation to the elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following elected Offices requiring such translation:

BR,CA,CN,GB,JP,KP,KR,NZ,PL,US

The following elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AP,EA,EP,AL,AM,AT,AU,AZ,BA,BB,BG,BY,CH,CU,CZ,DE,DK,EE,ES,FI,GE,GH,HU,ID,IL,IS,KE, KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM, TR,TT,UA,UG,UZ,VN,YU,ZW,OA

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report.

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Nestor Santesso

Telephone No. (41-22) 338.83.38

Facsimile No. (41-22) 740.14.35

2663297

Form PCT/IB/338 (July 1996)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		otification of Transmittal of International				
15409P WO	FOR FURTHER ACTION Prelimin	ary Examination Report (Form PCT/IPEA/416)				
International application No.	International filing date (day/month/year	1				
PCT/EP97/06463	19 November 1997 (19.11.1997	7) 19 November 1996 (19.11.1996)				
International Patent Classification (IPC) or na A61L 27/00	International Patent Classification (IPC) or national classification and IPC A61L 27/00					
	*					
Applicant						
Applicant BIOPHARM GESELLSCHAFT ZU	UR BIOTECHNOLOGISCHEN E MBH	ENTWICKLUNG VON PHARMAKA				
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.						
2. This REPORT consists of a total of4 sheets, including this cover sheet.						
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a to	These annexes consist of a total of sheets.					
3. This report contains indications relat	ing to the following items:					
I Basis of the report						
II Priority	II Priority					
III Non-establishment	of opinion with regard to novelty, invent	ve step and industrial applicability				
IV Lack of unity of invention						
v Reasoned statement	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;					
	citations and explanations supporting such statement					
VI Certain documents cited						
VII Certain defects in the international application						
VIII Certain observations on the international application						
Date of submission of the demand	Date of completic	on of this report				
30 March 1998 (30.03.1	998)	9 January 1999 (29.01.1999)				
Name and mailing address of the IPEA/EP European Patent Office	Authorized office	er				
D-80298 Munich, Germany	Talanhana No. 4	0.80.2200.0				

Translation

International application No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/EP97/06463

I. Basis of the report					
1. This report has been drawn on the basis of (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):					
ſ	\neg	the international	application as o	originally filed.	
5	\overline{X}	the description,	pages	1-23	, as originally filed,
			pages		_, filed with the demand,
		•			_, filed with the letter of,
			pages		_, filed with the letter of
ľ	X	the claims,	Nos	1-13	, as originally filed,
			Nos.		, as amended under Article 19,
					_ , filed with the demand,
			Nos		, filed with the letter of,
			Nos.		_ , filed with the letter of
ľ	X	the drawings,	sheets/fig	1/1	, as originally filed,
L					, filed with the demand,
			sheets/fig		, filed with the letter of,
			sheets/fig	 	, filed with the letter of
2. The ar	nendr	nents have resulte	ed in the cancel	lation of:	
		the description,	pages		
		the claims,	Nos.		
		the drawings,	sheets/fig		•
	_				
3.	This to go	report has been es beyond the discle	stablished as if one of stablished as filed, a	(some of) the and in the sindicated in the	nendments had not been made, since they have been considered e Supplemental Box (Rule 70.2(c)).
		•			
4. Additi	onal o	observations, if no	ecessary:		

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/EP 97/06463

YES

NO

1-11

12, 13 see Box V

V .	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement					
	Novelty (N)	Claims	1-13	YES		
		Claims		NO		
	Inventive step (IS)	Claims	1-13	YES		
	,	Claims		NO		

Claims

Claims

2. Citations and explanations

Industrial applicability (IA)

1) US-A-4 596 574 describes an implant material that contains BMP as osteoinductive protein and a matrix material of calcium phosphate and that can be produced by coprecipitation (see column 5, lines 52-60 and Claims 7 and 8).

The subject matter of the present claims differs therefrom by the presence of a matrix material of calcium phosphate as component B, which itself posseses osteogenic activity.

This distinguishing feature has the effect of preventing harmful tissue reactions such as anachoresis of connective tissue or inflammations.

This was not obvious to a person skilled in the art, and so the subject matter of the claims involves an inventive step.

2) The PCT does not contain uniform criteria for evaluating whether the subjects of the present Claims 12 and 13 have industrial applicability.

Patentability can also depend on the formulation of the claims. The EPO, for example, does not recognize

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/EP 97/06463

as industrially applicable the subject of claims to the medical use of a compound; however, it may allow claims to the first medical use of a known compound and the use of such a compound in the manufacture of a drug for a new medical use.